For the Inventor, By the Inventor

Enter assignee name

Ann Arbor, MI, United States of America

Esperion Therapeutics, Inc.

USPTO Granted Patents = 60

CIPO Patents = 3

EPO Patents = 10

Trademarks = 6

Forward Citations = 1,340

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Carmen Daniela Oniciu (30 out of 31 patents)

Jean-Louis Henri Dasseux (29 out of 33 patents)

Jean-Louis Henri Dasseux (13 out of 59 patents)

4. Richard Copp (8 out of 8 patents)

5. Mohamed Abdelnasser (8 out of 8 patents)

6. Christopher M Cimarusti (8 out of 8 patents)

7. Jonathan Lane (7 out of 8 patents)

8. Michael Barkman (7 out of 7 patents)

9. Rasidul Amin (7 out of 8 patents)

10. Arthur John Cooper (7 out of 8 patents)

11. Damodaragounder Gopal (7 out of 14 patents)

12. Philipp Selig (7 out of 8 patents)

13. Roger Schofield Newton (5 out of 11 patents)

14. Daniela Carmen Oniciu (3 out of 14 patents)

15. Hans Ageland (3 out of 7 patents)

Core Competencies:

Bempedoic Acid

Cholesterol Management

Fixed Dose Combinations

Apolipoprotein Mixtures

Cycloalkyl-Hydroxyl Compounds

Ketone Compounds

Dihydroxyl Compounds

Ether Compounds

Sulfide Compounds

Fourier Transform Mass Spectrometry

Cardiovascular Disease Treatment

Drug Administration

60 patents: Sort by Forward Citations

1. 12404227 - Methods of making bempedoic acid and compositions of the same (2025-09-02),

2. 12398087 - Methods of making bempedoic acid and compositions of the same (2025-08-26),

3. 12344578 - Salt forms of bempedoic acid and methods for using the same (2025-07-01),

4. 11987548 - Methods of making bempedoic acid and compositions of the same (2024-05-21),

5. 11926584 - Methods of making bempedoic acid and compositions of the same (2024-03-12),

6. 11760714 - Methods of making bempedoic acid and compositions of the same (2023-09-19),

7. 11744816 - Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease (2023-09-05),

8. 11613511 - Methods of making bempedoic acid and compositions of the same (2023-03-28),

9. 11407705 - Methods of making bempedoic acid and compositions of the same (2022-08-09),

10. 10941095 - Hydroxyl compounds and compositions for cholesterol management and related uses (2021-03-09),

11. 10912751 - Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease (2021-02-09),

12. 10118881 - Hydroxyl compounds and compositions for cholesterol management and related uses (2018-11-06),

13. 10047028 - Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses (2018-08-14),

14. 9624152 - Hydroxyl compounds and compositions for cholesterol management and related uses (2017-04-18),

15. 9610324 - Apolipoprotein mixtures (2017-04-04),

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Their goal is to provide efficient, convenient, and cost-effective solutions to address unmet medical needs. For over a decade, Esperion has been dedicated to advancing research and finding unique therapies to improve cardiovascular health. By utilizing their deep understanding of lipid biology, they continue to develop potential breakthrough therapies that can make a significant difference in patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

60 Patents

#14 in Ann Arbor, MI

#227 in Michigan

#5,778 in US

#11,645 in the World

Ann Arbor, MI, United States of America

Esperion Therapeutics, Inc.

Forward Citations = 1,340

48 inventors:

Carmen Daniela Oniciu (30 out of 31 patents)

Jean-Louis Henri Dasseux (29 out of 33 patents)

Jean-Louis Henri Dasseux (13 out of 59 patents)

4. Richard Copp (8 out of 8 patents)

5. Mohamed Abdelnasser (8 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…